+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Uterine Cancer Therapeutics & Diagnostics Market by Treatment Type, Diagnostic Product Type, Diagnostic Technology, End User, Route Of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Uterine Cancer Therapeutics & Diagnostics Market by Treatment Type, Diagnostic Product Type, Diagnostic Technology, End User, Route Of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Uterine Cancer Therapeutics & Diagnostics Market by Treatment Type, Diagnostic Product Type, Diagnostic Technology, End User, Route Of Administration, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896801
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The uterine cancer therapeutics and diagnostics market is entering a significant period of transformation, characterized by innovation in treatment modalities and diagnostic technologies. Demand for precise, scalable, and value-driven solutions is increasing among healthcare providers and industry leaders as clinical needs evolve and the regulatory landscape adapts accordingly.

Market Snapshot: Uterine Cancer Therapeutics & Diagnostics

The Uterine Cancer Therapeutics & Diagnostics Market grew from USD 23.95 billion in 2024 to USD 25.53 billion in 2025. It is expected to continue growing at a CAGR of 6.32%, reaching USD 34.61 billion by 2030. The primary keyword, uterine cancer therapeutics and diagnostics, underscores continuous innovation, reflecting both industry advances and shifting patient demographics. Market expansion is propelled by improved early detection tools, adoption of targeted and immunotherapies, and regulatory frameworks that support timely access to new solutions. Regional dynamics highlight robust North American performance, regulatory diversity in EMEA, and swift expansion in Asia-Pacific driven by investments in infrastructure and cancer control programs.

Scope & Segmentation

  • Treatment Types: Chemotherapy, hormonal therapy, immunotherapy, radiotherapy, surgery, targeted therapy (including monoclonal antibodies, PARP inhibitors, tyrosine kinase inhibitors).
  • Diagnostic Product Types: Cytology, histopathology, imaging (CT, MRI, PET, ultrasound), molecular diagnostics (FISH, next-generation sequencing, polymerase chain reaction).
  • Diagnostic Technologies: Flow cytometry, FISH, immunohistochemistry (automated platforms, manual assays), next-generation sequencing, polymerase chain reaction.
  • End Users: Ambulatory care centers, diagnostic laboratories, hospitals, oncology clinics, research institutes.
  • Route of Administration: Intravenous, oral.
  • Distribution Channels: Hospital pharmacy, retail pharmacy, specialty pharmacy.
  • Regional Coverage: Americas (United States—including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio—Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies: Merck & Co., AstraZeneca, Pfizer, Bristol-Myers Squibb, Novartis, Roche, Illumina, Thermo Fisher Scientific, QIAGEN, Myriad Genetics.

Key Takeaways and Strategic Insights

  • Market growth is anchored in widespread adoption of personalized treatment pathways, leveraging biomarkers and molecular profiling to enhance therapeutic precision and monitor disease resistance.
  • Diagnostic innovation is accelerating, with next-generation sequencing, liquid biopsy, and AI-driven histopathology contributing to earlier cancer detection and streamlined clinical workflows.
  • Emergence of minimally invasive surgeries and advanced radiotherapy supports reductions in post-treatment morbidity and overall healthcare costs, addressing both patient quality of life and resource optimization.
  • Strategic alliances between biopharmaceutical and diagnostics companies enable companion diagnostic readiness—shortening time-to-market for novel agents and integrated test solutions.
  • Mergers, acquisitions, and licensing collaborations are driving portfolio expansion, particularly in targeted therapies and molecular testing platforms, as firms seek differentiation through specialization and co-development models.

Tariff Impact on Market Dynamics

The scheduled introduction of new U.S. tariffs in 2025 is anticipated to affect supply chains and pricing strategies for therapeutics and diagnostic products. Increased import duties on pharmaceutical ingredients, specialty reagents, and complex imaging equipment may raise manufacturing costs. Stakeholders are employing risk mitigation through diversified supplier networks, scenario planning, and regional manufacturing investments to maintain efficiency and competitiveness. Laboratories, manufacturers, and procurement teams must continuously adapt sourcing and pricing models to manage these evolving cost structures.

Methodology & Data Sources

This research report uses a hybrid methodology, combining primary interviews with leading oncologists, pathologists, healthcare executives, and procurement managers across global markets. Secondary research included detailed analysis of peer-reviewed publications, clinical trial registries, regulatory filings, corporate financials, and public health databases. Scenario-based modeling and expert cross-validation underpin reliability and accuracy.

Why This Report Matters to Senior Decision-Makers

  • Enables targeted R&D investment and portfolio optimization by providing segmented market insights and highlighting emerging therapeutics.
  • Facilitates risk management and strategic planning in response to evolving regulatory, reimbursement, and trade environments.
  • Supports informed partnership evaluation and commercial strategy development by mapping competitor landscapes and technology adoption trends.

Conclusion

This analysis synthesizes a complex landscape of therapeutics and diagnostics, regional expansion, and evolving supply chain dynamics. Senior leaders can leverage these insights to inform investment, operational, and partnership decisions in the uterine cancer market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Uterine Cancer Therapeutics & Diagnostics Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Antimetabolites
8.2.2. Platinum Compounds
8.2.3. Taxanes
8.3. Hormonal Therapy
8.4. Immunotherapy
8.5. Radiotherapy
8.6. Surgery
8.7. Targeted Therapy
8.7.1. Monoclonal Antibodies
8.7.2. Parp Inhibitors
8.7.3. Tyrosine Kinase Inhibitors
9. Uterine Cancer Therapeutics & Diagnostics Market, by Diagnostic Product Type
9.1. Introduction
9.2. Cytology
9.3. Histopathology
9.4. Imaging
9.4.1. Computed Tomography
9.4.2. Magnetic Resonance Imaging
9.4.3. Positron Emission Tomography
9.4.4. Ultrasound
9.5. Molecular Diagnostics
9.5.1. Fluorescence In Situ Hybridization
9.5.2. Next Generation Sequencing
9.5.3. Polymerase Chain Reaction
10. Uterine Cancer Therapeutics & Diagnostics Market, by Diagnostic Technology
10.1. Introduction
10.2. Flow Cytometry
10.3. Fluorescence In Situ Hybridization
10.4. Immunohistochemistry
10.4.1. Automated Platforms
10.4.2. Manual Assays
10.5. Next Generation Sequencing
10.6. Polymerase Chain Reaction
11. Uterine Cancer Therapeutics & Diagnostics Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Diagnostic Laboratories
11.4. Hospitals
11.5. Oncology Clinics
11.6. Research Institutes
12. Uterine Cancer Therapeutics & Diagnostics Market, by Route Of Administration
12.1. Introduction
12.2. Intravenous
12.3. Oral
13. Uterine Cancer Therapeutics & Diagnostics Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Retail Pharmacy
13.4. Specialty Pharmacy
14. Americas Uterine Cancer Therapeutics & Diagnostics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. AstraZeneca PLC
17.3.3. Pfizer Inc.
17.3.4. Bristol-Myers Squibb Company
17.3.5. Novartis AG
17.3.6. Roche Holding AG
17.3.7. Illumina, Inc.
17.3.8. Thermo Fisher Scientific Inc.
17.3.9. QIAGEN N.V.
17.3.10. Myriad Genetics, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TAXANES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CYTOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY AUTOMATED PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MANUAL ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 81. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 82. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 83. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 84. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 86. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 87. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 89. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 94. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 95. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 97. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 99. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 100. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 150. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 151. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 152. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 153. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 156. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 161. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 162. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 163. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 164. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 165. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 167. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 183. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 184. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 186. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 187. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 188. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 189. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 194. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 195. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 196. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 197. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 198. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 199. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 200. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 215. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 216. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 217. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 218. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 219. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 220. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 226. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 227. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 228. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 230. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 231. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 238. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 239. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 241. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 242. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 243. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 244. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 249. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 250. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 251. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 252. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 253. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 254. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 255. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 260. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 261. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 262. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 263. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 264. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 265. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 266. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. QATAR UTERINE CANC

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Uterine Cancer Therapeutics & Diagnostics market report include:
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Roche Holding AG
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Myriad Genetics, Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 25.53 Billion
Forecasted Market Value ( USD ) by 2030 $ 34.61 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Uterine Cancer Therapeutics and Diagnostics - Global Strategic Business Report - Product Image

Uterine Cancer Therapeutics and Diagnostics - Global Strategic Business Report

  • Report
  • 173 Pages
  • Global
From
Pancreatic Cancer Precision Medicine Market Size, Share & Trends Analysis Report by Therapeutic Approach (Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations), Diagnostic Technology, and Region with Growth Forecasts, 2025-2030 - Product Image

Pancreatic Cancer Precision Medicine Market Size, Share & Trends Analysis Report by Therapeutic Approach (Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations), Diagnostic Technology, and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Epigenetic Drug and Diagnostic Technology - Global Strategic Business Report - Product Image

Epigenetic Drug and Diagnostic Technology - Global Strategic Business Report

  • Report
  • 377 Pages
  • Global
From
Immunochemistry Diagnostic Devices and Equipment Market Report 2025 - Product Image

Immunochemistry Diagnostic Devices and Equipment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Rehabilitation Diagnostic Equipment Market by Product Type, Application, End User - Global Forecast to 2030 - Product Image

Rehabilitation Diagnostic Equipment Market by Product Type, Application, End User - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.